India's Piramal investing $55M in API production

Piramal Pharma Solutions, which bought Michigan-based Ash Stevens last year, says it is investing $55 million across its manufacturing network to improve and expand its API manufacturing capabilities.

Indian CDMO Piramal Pharma Solutions is beefing up its global API production, including in the U.S., where it has expanded in recent years.

The company said on Tuesday that it would invest $55 million across its network. In addition to upgrades in manufacturing automation and IT across its entire network, specific projects include expanding its early development capabilities at a site in Morpeth, U.K., and its high-potency drug capabilities at its site in Riverview, Michigan.

RELATED: India's Piramal buys another U.S. manufacturer


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Piramal picked up the Michigan operation last year when it agreed to pay up to $53 million in cash and milestone payments for Riverview-based Ash Stevens. With that deal, it acquired 60,000 square feet of facilities, eight chemical drug development and production laboratories, and six full-scale production areas, including facilities for high-potency API manufacturing.

RELATED: India's Piramal to buy U.S. maker of sterile injectables, antibody drug conjugates

In January 2015, Piramal agreed to pay $30.65 million to buy Coldstream Laboratories from the University of Kentucky to get its expertise in sterile injectable medications.

Indian companies have been aggressive buyers of small- to medium-sized U.S. operations in the last few years. Mumbai-based Lupin Pharmaceuticals bought two New Jersey generics companies last year for a total of almost $900 million. In 2015, Cipla paid $550 million for InvaGen Pharmaceuticals, a Hauppauge, New York-based generics maker, and its marketing operation, picking up a 350,000-square-foot manufacturing plant in the deal.


Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.